Radiomics Biomarkers Correlate with CD8 Expression and Predict Immune Signatures in Melanoma Patients.

Radiomics Biomarkers Correlate with CD8 Expression and Predict Immune Signatures in Melanoma Patients.

Publication date: Jun 01, 2021

Treatment for metastatic melanoma includes targeted and/or immunotherapy. Although many patients respond, only a subset has complete response. As late-stage patients often have multiple tumors in difficult access sites, non-invasive techniques are necessary for the development of predictive/prognostic biomarkers. PET/CT scans from 52 patients with stage III/IV melanoma were assessed and CT image parameters were evaluated as prognostic biomarkers. Analysis indicated patients with high standard deviation or high mean of positive pixels (MPP) had worse progression-free survival (P = 0. 00047 and P = 0. 0014, respectively) and worse overall survival (P = 0. 0223 and P = 0. 0465, respectively). Whole-exome sequencing showed high MPP was associated with BRAF mutation status (P = 0. 0389). RNA-sequencing indicated patients with immune “cold” signatures had worse survival, which was associated with CT biomarker, MPP4 (P = 0. 0284). Multiplex immunofluorescence confirmed a correlation between CD8 expression and image biomarkers (P = 0. 0028). IMPLICATIONS: CT parameters have the potential to be cost-effective biomarkers of survival in melanoma, and reflect the tumor immune-microenvironment. VISUAL OVERVIEW: http://mcr. aacrjournals. org/content/molcanres/19/6/950/F1. large. jpg.

Concepts Keywords
Ct Http
F1 Tumor microenvironment
Immunotherapy Radiomics
Late Melanoma
Stage Medicine
Biomarkers
Branches of biology

Semantics

Type Source Name
disease MESH Melanoma
pathway KEGG Melanoma
disease MESH tumors
disease MESH development

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *